Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan.
Yohei IsomuraYuichiro ShiraiMasataka KuwanaPublished in: Rheumatology (Oxford, England) (2022)
Our findings suggest potential benefits of prolonged tocilizumab use in dcSSc patients. The discontinuation of tocilizumab can lead to the progression of skin and visceral manifestations. Tapering rather than the discontinuation of tocilizumab is a viable option in dcSSc patients who experience remarkable clinical improvement.
Keyphrases
- rheumatoid arthritis
- systemic sclerosis
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- interstitial lung disease
- end stage renal disease
- disease activity
- chronic kidney disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- type diabetes
- risk assessment
- systemic lupus erythematosus
- adipose tissue
- metabolic syndrome
- soft tissue
- human health
- wound healing